BURLINGTON, Mass.--(BUSINESS WIRE)--ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, will present at the 2019 RBC Capital Markets Global Healthcare Conference on May 21, 2019 at 3:35 p.m. ET at the InterContinental New York Barclay in New York City.
The live webcast of the presentation will be available via the “Investors & Media” section of ArQule’s website, www.arqule.com, under “Events & Presentations.” A replay of the webcast will be available shortly after the conclusion of the presentation.
About ArQule
ArQule is a biopharmaceutical company engaged
in the research and development of targeted therapeutics to treat
cancers and rare diseases. ArQule’s mission is to discover, develop and
commercialize novel small molecule drugs in areas of high unmet need
that will dramatically extend and improve the lives of our patients. Our
clinical-stage pipeline consists of four drug candidates, all of which
are in targeted, biomarker-defined patient populations, making ArQule a
leader among companies our size in precision medicine. ArQule’s pipeline
includes: ARQ 531, an orally bioavailable, potent and reversible dual
inhibitor of both wild type and C481S-mutant BTK, in phase 1 for
patients with B-cell malignancies refractory to other therapeutic
options; miransertib (ARQ 092), a potent and selective inhibitor of the
AKT serine/threonine kinase, planned to initiate registrational trial
cohorts in Proteus syndrome and PROS in 2019, and in phase 1b in
combination with the hormonal therapy, anastrozole, in patients with
advanced endometrial cancer; ARQ 751, a next generation highly potent
and selective AKT inhibitor, in phase 1 for patients with AKT1 and PI3K
mutations; and derazantinib, a multi-kinase inhibitor designed to
preferentially inhibit the fibroblast growth factor receptor (FGFR)
family, in a registrational trial for iCCA in collaboration with Basilea
and Sinovant. ArQule’s current discovery efforts are focused on the
identification and development of novel kinase inhibitors, leveraging
the Company’s proprietary library of compounds.
